share_log

Argus Research Downgrades Silk Road Medical to Sell

Benzinga ·  Jul 11 19:22

Argus Research analyst Steve Silver downgrades Silk Road Medical (NASDAQ:SILK) from Buy to Sell.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment